Vivek Subbiah, MD on RET inhibitorr: Common Questions @VivekSubbiah #ASCO2020 @MDAndersonNews #ASCO

Vivek Subbiah, MD on RET inhibitorr: Common Questions @VivekSubbiah #ASCO2020 @MDAndersonNews #ASCO

Cancer-News

1 week
6 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 1
Category:
Description:

Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

Read here: https://meetinglibrary.asco.org/record/186874/abstract

Up Next Autoplay